

## Disclosures

### Personal Commercial (27)

| Company Name                     | Relationship Category                        | Compensation Level       | Topic Area(s)                      |
|----------------------------------|--|--------------------------|------------------------------------|
| <i>Self</i>                      |  |                          |                                    |
| Abbott Laboratories              | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Alnylam                          | Research/Research Grants                     | Significant (>= \$5,000) | Other                              |
| Alnylam                          | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| AstraZeneca Pharmaceuticals      | Research/Research Grants                     | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| AstraZeneca Pharmaceuticals      | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Avidity Biopharma                | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Axon Therapeutics                | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Baim Clinical Research Institute | Other - Adjudicator for CEC                  | Significant (>= \$5,000) | General Cardiology                 |
| Bayer Healthcare Pharmaceuticals | Research/Research Grants                     | None (\$0)               | Heart Failure and Cardiomyopathies |
| biofourmis                       | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Cytokinetics                     | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| endotronix                       | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| GlaxoSmithKline                  | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Other                              |
| Medpace                          | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | General Cardiology                 |
| Merck & Co., Inc.                | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| New Amsterdam                    | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | General Cardiology                 |
| Novartis Corporation             | Research/Research Grants                     | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Novartis Corporation             | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Parexel                          | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Pfizer Inc                       | Research/Research Grants<br>‡ GARDEN TIMI-75 | None (\$0)               | Heart Failure and Cardiomyopathies |
| Regeneron                        | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| River2Renal                      | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Roche                            | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | General Cardiology                 |
| scPharma                         | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Teva                             | Consultant Fees/Honoraria                    | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| TIMI Study Group                 | Other - Adjudication for CEC                 | Significant (>= \$5,000) | General Cardiology                 |
| Volta medical                    | Consultant Fees/Honoraria                    | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (2)

| Year        | Case Title                     | Represented | Description  | Compensation       |
|-------------|--------------------------------|-------------|--|--------------------|
| <i>Self</i> |                                |             |  |                    |
| 2019        | Cardiomyopathy                 | Defendant   | Failure to diagnose and treat hemochromatosis involving the heart                | Modest (< \$5,000) |
| 2018        | Out of Hospital Cardiac Arrest | Plaintiff   | Failure to defibrillate patient with available AED during out of hospital arrest | Modest (< \$5,000) |

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 8/26/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement | Signed on 8/26/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo | Signed on 8/26/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement | Signed on 8/26/2025

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.